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RAPIDIRON: Reducing Anaemia in
Pregnancy in India—a 3-arm, randomizedcontrolled trial comparing the effectiveness
of oral iron with single-dose intravenous
iron in the treatment of iron deficiency
anaemia in pregnant women and reducing
low birth weight deliveries
Richard J. Derman, Shivaprasad S. Goudar, Simal Thind* , Sudhir Bhandari, Zubair Aghai, Michael Auerbach,
Rupsa Boelig, Umesh S. Charantimath, Rosemary Frasso, M. S. Ganachari, Kusum Lata Gaur, Michael K. Georgieff,
Frances Jaeger, S Yogeshkumar, Parth Lalakia, Benjamin Leiby, Mita Majumdar, Amarjeet Mehta, Seema Mehta,
Sudhir Mehta, Stephen T. Mennemeyer, Amit P. Revankar, Dharmesh Kumar Sharma, Vanessa Short,
Manjunath S. Somannavar, Dennis Wallace, Hemang Shah, Manjula Singh, Sufia Askari, Mrutyunjaya B. Bellad and
the RAPIDIRON Trial Group

Abstract
Background: Anaemia is a worldwide problem and iron deficiency is the most common cause. In pregnancy,
anaemia increases the risk of adverse maternal, foetal and neonatal outcomes.
India’s anaemia rate is among the highest in the world with India’s National Family Health Survey indicating over
50% of pregnant women were affected by anaemia.
India’s Anaemia Mukt Bharat-Intensified National Iron Plus Initiative aims to reduce the prevalence of anaemia
among reproductive-age women, adolescents and children by 3% per year and facilitate the achievement of a
Global World Health Assembly 2025 objective to achieve a 50% reduction of anaemia among women of
reproductive age.
However, preliminary results of the NFHS-5 survey completed in 2020 indicate that anaemia rates are increasing in
some states and these targets are unlikely to be achieved. With oral iron being the first-line treatment for iron
deficiency anaemia (IDA) in pregnancy, these results are likely to be impacted by the side effects, poor adherence
to tablet ingestion and low therapeutic impact of oral iron. These reports suggest a new approach to treating IDA,
specifically the importance of single-dose intravenous iron infusions, may be the key to India effectively reaching its
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targets for anaemia reduction.
Methods: This 3-arm, randomized controlled trial is powered to report two primary outcomes. The first is to assess
whether a single dose of two different intravenous formulations administered early in the second trimester of
pregnancy to women with moderate IDA will result in a higher percentage of participants achieving a normal for
pregnancy Hb concentration at 30–34 weeks’ gestation or just prior to delivery when compared to participants
taking standard doses of oral iron. The second is a clinical outcome of low birth weight (LBW) (< 2500 g), with a
hypothesis that the risk of LBW delivery will be lower in the intravenous iron arms when compared to the oral iron
arm.
Discussion: The RAPIDIRON trial will provide evidence to determine if a single-dose intravenous iron infusion is
more effective and economically feasible in reducing IDA in pregnancy than the current standard of care.
Trial registration: Clinical Trials Registry – India CTRI/2020/09/027730. Registered on 10 September 2020, http://ctri.
nic.in/Clinicaltrials/showallp.php?mid1=46801&EncHid=&userName=anemia%20in%20pregnancy
Keywords: Anaemia, Iron deficiency anaemia, Anaemia in pregnancy, Intravenous iron, Oral iron, Low birth weight
infants
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Introduction
Background and rationale {6a}

Anaemia is a worldwide problem with iron deficiency
anaemia (IDA) being the most common cause [1]. When
occurring in pregnancy, anaemia increases the risk of
adverse maternal, foetal and neonatal outcomes [2, 3].
These adverse outcomes include maternal mortality,
preterm and low birth weight (LBW) deliveries, perinatal
and neonatal deaths and long-term developmental sequelae in the surviving offspring [4].
Anaemia rates are among the highest in South Asia,
and India’s National Family Health Survey (NFHS-4) for
2015–2016 indicated that anaemia with haemoglobin
(Hb) <11.0 g/dL affected over 50% of pregnant women
[5]. Anaemia during pregnancy is a major contributing
factor to the nearly 60% of children 6–59 months of age
classified as anaemic in the same survey with an Hb
level of <11 g/dL. Optimal foetal, neonatal and
childhood brain growth and development require
adequate iron [6, 7]. However, women with moderate to
severe anaemia during the late 2nd and early 3rd
trimesters of pregnancy are often unable to make up
their iron deficit. Thus, despite active transport via the
placenta, insufficient iron may be transmitted to the
developing foetus with consequent negative sequelae,
including long-term neurodevelopmental impairment of
the newborn [8].
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For nearly 40 years, India’s first-line treatment for IDA
in pregnancy has been oral iron; however, side effects,
poor adherence to tablet ingestion and low therapeutic
impact are among reasons for consideration of a new
standard for treatment of IDA in pregnant women [9].
The Anaemia Mukt Bharat programme

The Government of India has given high priority to
reducing the prevalence of anaemia in India, and several
initiatives have been directed towards this objective. The
latest anaemia strategy, built upon prior national
programmes and supported by the Ministry of Health
and Family Welfare, was presented in a 2018
publication, Anaemia Mukt Bharat-Intensified National
Iron Plus Initiative [10]. The same overall strategy
remains in effect, but a few changes have been made to
specific intervention guidelines which can be viewed
online [11].
The Anaemia Mukt Bharat programme encompasses
a national goal of reducing prevalence of anaemia
among children, adolescents and reproductive-age
women at the rate of 3% a year. It also aims to facilitate
the achievement of a Global World Health Assembly objective declared in 2012, to achieve a 50% reduction of
anaemia among women of reproductive age by 2025
[10].
Existing literature

A study of Chinese pregnant women found that daily
oral iron, initiated at or prior to 20 weeks’ gestation and
continued until delivery, improved maternal iron
parameters; however, 45% of the babies born to these
women were iron deficient suggesting that oral iron
supplementation may not optimally reach the
developing foetus [12]. Published evidence confirms that
iron deficiency in infancy is associated with an increase
in cognitive and behavioural abnormalities, which may
persist for decades despite later iron repletion [13, 14].
While one of the primary outcomes for this study is the
risk of LBW delivery (a leading cause of under-5 mortality and an independent risk for poorer neurodevelopment), anaemia in pregnancy is associated with other
adverse pregnancy outcomes such as increased rates of
preterm birth and perinatal and neonatal mortality [15].
Among a cohort of 92,247 Indian and Pakistani
pregnant women, in a 2019 study, 87.8% were anaemic
[15]. When classified by anaemia severity, the highest
percentage of pregnant women, or 49.2%, were in the
moderate group (Hb 7–9.9 g/dL), and secondary analysis
found that these moderately anaemic women had higher
rates of poor pregnancy outcomes than those with
higher Hb concentrations. For pregnant women residing
in under-resourced countries and having mild anaemia
(Hb 10–10.9 g/dL), research findings have not shown a
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consistent relationship between anaemia and poor pregnancy outcomes [4]. Thus, for this research, only pregnant women with moderate IDA will be eligible for
randomization.
The Cochrane Collaboration reported a scarcity of
quality trials that assessed clinical maternal and neonatal
effects of iron administration to anaemic, pregnant
women [16]. The Cochrane reviewers indicated the need
for large, high-quality trials that assess both clinical outcomes and treatment effects. This need has not been adequately met, especially in terms of assessing the efficacy
of newer treatment approaches, specifically the use of
single-dose intravenous (IV) iron during pregnancy.
Implementing the proposed study will address this identified but unmet need and increase the likelihood that
the guidelines and recommendations of India’s respected
health organizations will continue to undergo refinement. Subsequently, criteria for establishing feasibility,
convenience and cost-effectiveness will be better met to
enable broader and more rapid implementation and
scale-up of optimal treatment approaches.
Intravenous iron and iron deficiency anaemia

IV iron has many advantages as a treatment of IDA. The
ability to give a larger dose in a single IV injection leads
to increased bioavailability of iron and more rapid
correction of IDA [17–20]. This is particularly important
in pregnancy to ensure iron sufficiency in the developing
foetus [21–23]. In a study of women treated with IV
iron, none of the newborns were diagnosed with iron
deficiency anaemia [24]. Furthermore, this method
reduces the risk of poor adherence to treatment so often
seen with oral iron. Study findings also indicate that IV
iron is safe (with no serious adverse events reported),
less toxic and more effective than oral iron in the
treatment of IDA in pregnant women [25, 26].
This study will be a 3-arm, randomized-controlled trial
comparing the effectiveness of two IV iron formulations:
ferric carboxymaltose and ferric derisomaltose (formerly
known as iron isomaltoside), with oral iron in the treatment of IDA in pregnant women and in reducing low
birth weight deliveries [27–29]. Two IV iron formulations, approved for marketing in India, will be used with
the aim of demonstrating that pregnant women, randomly assigned to either of the formulations, will have a
higher rate of conversion to a non-anaemic state when
compared to the oral iron comparator arm.
Summary

This research aims to assess the efficacy of a single dose
of IV iron, administered early in the second trimester of
pregnancy for the treatment of moderate IDA, in
achieving a greater percentage of women with a normal
for pregnancy Hb concentration of >11 g/dL by delivery,
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when compared to a control arm provided with an oral
iron regimen that is the primary and current standard of
care in India.
Published data suggest that IV iron is a safe and more
effective treatment of IDA in pregnancy than is oral
iron. This newer approach to the treatment of IDA must
be ideally evaluated through a randomized control trial
in a population that continues to be greatly affected by
this problem and has a critical need to employ more
effective management strategies.
Objectives {7}
Study hypotheses

This trial incorporates the following study hypotheses:
Primary hypothesis #1 Singleton pregnant participants
with moderate iron deficiency anaemia who are
randomly assigned to an IV iron arm and receive, early
in the second trimester of pregnancy, a single dose of IV
iron for treatment of anaemia and the currently
recommended daily dose of folic acid will have a higher
conversion rate to non-anaemic status (or Hb >11 g/dL)
in the last trimester of pregnancy at either a 30–34 week
antenatal visit or prior to delivery than pregnant women
assigned to an oral iron arm and provided a standard
dose of iron and folic acid tablets for anaemia treatment.
Primary hypothesis #2 The pregnant participants
assigned to an IV iron treatment group will have a lower
risk of LBW deliveries (a 20% relative reduction)
compared to pregnant women in the oral iron group.
Secondary hypothesis To determine if administration of
either of the two IV iron formulations used in the study
will have a more favourable impact on other maternal
and neonatal outcomes than among women provided
daily oral iron. This will be assessed through reported
differences between study arms at specified timepoints
for the secondary outcomes listed in section {12}.
Trial design {8}

This study is a 3-arm randomized-controlled trial with
two primary outcomes of interest. The research is designed to assess if a single dose of an IV iron formulation (ferric carboxymaltose in intervention arm 1 or
ferric derisomaltose (formerly known as iron isomaltoside) in intervention arm 2), provided for treatment of
moderate IDA in pregnant women, will result in a
greater percentage of pregnant participants achieving a
normal for pregnancy Hb concentration of >11 g/dL by
the third trimester, when compared to the comparator
arm (arm 3) given oral iron. Moderate IDA has been defined employing the WHO definition for all cause anaemia severity, Hb < 7 g/dL (severe); 7–9.9 g/dL
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(moderate); 10–10.9 g/dL (mild); and >11 g/dL (non-anaemic or normal) [30]. Those eligible to receive iron
treatment must also show laboratory values of serum
transferrin saturation (TSAT) < 20% and/or ferritin < 30
ng/mL.
The second primary outcome is that of low birth
weight (LBW) (< 2500 g), one of several adverse
pregnancy outcomes associated with IDA. The
hypothesis for reporting on this clinical outcome is that
the risk of LBW delivery for participants randomized to
the IV iron arms will be significantly lower when
compared to the risk of LBW delivery for participants
randomly assigned to the oral iron arm.
Approximately 4320 pregnant women who meet
eligibility criteria and have Hb concentrations of 7 to 9.9
g/dL with confirmed IDA will be randomized 1:1:1 to
one of two IV iron intervention arms or to the oral iron
arm.

Methods: participants, interventions and
outcomes
Study setting {9}

The study will be carried out in India with participants
recruited during an antenatal care visit made to
participating community health and primary health
centres (CHCs and PHCs) in the states of Karnataka and
Rajasthan.
Eligibility criteria {10}

Inclusion criteria for screening and consent are as
follows: (1) pregnant women between 18 and 40 years of
age and capable of giving informed consent; (2) Hb
concentration of 7–10.4 g/dL (as per the available point
of care laboratory report); (3) expressed intent and
expectations for remaining in the designated research
area during the pregnancy and delivering at a facility in
or near the research area as well as remaining in the
area to enable study participation and data collection
consistent with the research protocol; and (4) expressed
willingness that specifically includes agreement to
randomization to the standard care study arm (of oral
iron) or to one of the two arms involving treatment with
single-dose IV iron.
Additional inclusion criteria for randomization and
continued study participation include (1) presence of a
live singleton, intrauterine foetus and dating ultrasound
that indicates a pregnancy that, at randomization, would
be between the beginning of week 14 and prior to 17
weeks 0 days, and (2) iron deficiency anaemia defined
for this study as moderate anaemia with Hb
concentration level between 7 and 9.9 g/dL and serum
transferrin saturation (TSAT) < 20% and/or serum
ferritin < 30 ng/mL.
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Exclusion criteria include (1) foetal anomaly if
detectable when an initial ultrasound is done to date the
pregnancy (subsequent discovery of a foetal anomaly is
not viewed as an exclusion); (2) a history of
cardiovascular disease, hemoglobinopathy or other
disease or condition considered a contraindication for
treatment, including conditions recommended for
exclusion by the manufacturers of oral or IV iron to be
used in the study; and (3) any condition that, in the
opinion of the consenting healthcare provider, warrants
study exclusion.
Who will take informed consent? {26a}

Women will be screened for their eligibility to
participate in the study at their first antenatal visit at
participating CHCs and PHCs. If no exclusionary criteria
are known to apply, pregnant women will be educated
about the study, have all their questions answered and
be given the opportunity to consent to participate.
Consent will be obtained by a trained healthcare
provider or research staff member at the CHC or PHC.
Following review of the consent and medication
procedures, the woman will be asked to confirm and
document her willingness to participate in the study by
signing the consent form. If the participant is unable to
sign, her thumbprint will indicate written approval. Both
the staff member and the study participant will retain
signed copies of the form. If a prospective participant is
not prepared to consent she will be given the option to
take the form home to discuss participation with her
family before signing.
All staff responsible for obtaining consent will be
trained and certified in the protection of human subjects
and study-specific consent procedures. Each site will be
provided with a model informed consent form, developed by the research team.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}

When obtaining informed consent, participants will be
informed of which biological specimens will need to be
collected, at what timepoint as well as the reason for
such studies. They will also be informed that their data
will be de-identified and stored in a secure database and
that any data released will not be identifiable.
The consent procedure includes a condition wherein
participants are specifically asked to consent to the use
of data collected as part of the study or information
about outcomes under study for unrestricted scientific
purpose(s) only. They are also given the option to
consent to being contacted in the future regarding
participation in other related research studies.
Participants will be told they can withdraw consent at
any time during the trial.
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Interventions
Explanation for the choice of comparators {6b}

This 3-arm study will incorporate two IV iron formulations, ferric carboxymaltose in arm 1 and ferric derisomaltose in arm 2, and a comparator arm of a standard
dose of oral iron in arm 3. Two IV iron formulations are
being compared with the aim of demonstrating effectiveness of either in the treatment of IDA when compared
to oral iron.
Both IV iron formulations selected for use in this
study are approved and available commercially in India,
and both are proposed for the following reasons: (1)
they allow single-dose infusions of up to 1 g of iron, (2)
they have a proven track record of efficacy and availability in many countries of the world, (3) they are associated with very low rates of adverse events, (4) highquality studies show no difference in severe side effects
among available IV iron formulations and (5) there is
greater probability that inclusion of more than one
single-dose formulation will be instrumental in driving
down market prices and perhaps lead to public sector
pricing and greater utilization.
Oral iron will be used as the comparator arm as this is
currently the first-line treatment for mild and moderate
IDA in pregnancy.
Intervention description {11a}

Ferric carboxymaltose (Revofer Lupin) will be sourced in
500-mg vials. Ferric derisomaltose (Jilazo Lupin) will
also be sourced in 500-mg vials.
Pregnant women randomly assigned to an IV iron arm
at the third study visit will receive their single-dose IV
infusion at a participating CHC. Prior to beginning the
infusion, the pregnant woman will be counselled about
the infusion procedure and the risks and benefits before
confirming her willingness to proceed.
If the participant weighs more than 50 kg, they will
receive the assigned single dose formulation of 1000 mg
of iron; but women under 50 kg will receive a lower
dose of iron as determined by a formula that has been
recommended by both manufacturers of 20 mg iron/kg
body weight.
Oral iron will be given to arm 3 in the form of 60mg
Ferrous Sulphate tablets given to anaemic women twice
daily.
In all three study arms, participants will receive 180
tablets of folic acid (500 mcg) once daily and one tablet
of albendazole (400 mg) after randomization in the
second trimester of pregnancy.
Criteria for discontinuing or modifying allocated
interventions {11b}

Interventions will be discontinued at any time under the
following circumstances: (1) if the participant withdraws
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consent; (2) if the investigator determines the
intervention is a threat to the participant’s health, safety
and/or wellbeing; or (3) if the participant experiences
adverse effects requiring the intervention be
discontinued.
Strategies to improve adherence to interventions {11c}

Accredited Social Health Activists (ASHAs) who live
within the communities of recruiting CHCs and PHCs
will support the study team (with authorization of the
supervising health officials) and will be available to
accompany potential participants to facilities for
screening, dating of the pregnancy (by ultrasound), for
randomization followed by treatment of anaemia,
antenatal monitoring and delivery, and the 42-day postdelivery visit. ASHAs who have received education on
IDA can be an additional source of information about
the study.
Participants in the oral iron arm will be given clear
instructions about how to take the tablets and will be
asked at subsequent visits if they are taking their
medication and if not, the reasons for this. Answers will
be recorded on appropriate case report forms (CRF).
During the consent process, potential participants will
be informed about the randomization process and
procedures
if
they
are
found
eligible
for
randomization—that is, they will either be provided oral
iron and other components of standard care or be given
a single IV iron infusion. Participants will be counselled
on the risks and benefits of treatment relevant to all
study arms during the consent process.
Once randomized, and regardless of treatment arm,
participants will be encouraged to follow the treatment
plan for their study arm and attend the study visits as
instructed. Visits follow a schedule of standard antenatal
care that will also provide an opportunity to monitor
participant progress and encourage adherence to the
treatment plan.
Noncompliance
with
the
plan
for
iron
supplementation may be less for women randomly
assigned to an IV iron intervention as supplementation
during pregnancy would typically be complete after
receipt of a single IV iron infusion unless referral,
assessment and additional treatment is required.
Relevant concomitant care permitted or prohibited during
the trial {11d}

Unscheduled healthcare visits may occur for an enrolled,
randomized study participant. If this occurs, information
about this visit will be collected on a specific
unscheduled healthcare visit CRF.
Oral iron should not be taken by a pregnant woman
that receives an IV iron infusion in accordance with the
manufacturer guidelines. If a participant takes oral iron
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having received an IV iron infusion, a protocol deviation
would be noted.
Any use of oral iron, outside of that used by
participants in the oral iron arm of the study, is
considered an exclusion criterion.
The antenatal care provider seeing an enrolled and
randomized study participant will make decisions about
care that may be required because of other (nonanaemic) pregnancy complications or other healthrelated issues. It is expected that the provider will offer
standard of care to the pregnant woman in treating nonanaemia issues or other non-pregnancy related health
concerns that may arise.
Provisions for post-trial care {30}

The last scheduled study visit occurs at approximately
42 days postpartum. It would be expected that
healthcare providers will deliver standard of care and
specify the need for follow-up care for both the mother
and baby as deemed necessary.
Outcomes {12}
Primary outcomes

The first of two primary outcomes is to evaluate
whether a single dose of IV iron (ferric carboxymaltose
in intervention arm 1 and ferric derisomaltose in
intervention arm 2, administered early in the second
trimester of pregnancy for treatment of moderate IDA,
will result in a greater percentage of pregnant
participants in the IV iron arms achieving a normal for
pregnancy Hb concentration of >11 g/dL in the third
trimester of pregnancy, confirmed at either a 30–34week antenatal visit or prior to delivery, when compared
to those in the oral iron comparator arm (arm 3).
The second primary outcome is to evaluate the
incidence of low birth weight (< 2500 g), one of several
adverse pregnancy outcomes reported to be associated
with IDA. The hypothesis for this clinical outcome is
that the risk of LBW delivery for participants
randomized to the IV iron arms will be 20% lower when
compared to the risk of LBW delivery for participants
randomly assigned to the oral iron arm.
Secondary outcomes

Among the secondary outcomes to be recorded are
changes in Hb concentration, variation in participant
iron indices at specified timepoints (TSAT and ferritin,
changes in cord blood Hb and other iron indices of cord
blood (Fe/TIBC (TSAT) and ferritin), weight gain of
participants by trimester of pregnancy, mode of delivery/
C-section, antepartum and severe postpartum
haemorrhage, hypertensive disorders, maternal or
neonatal infections including documented COVID-19,
maternal and neonatal mortality, preterm and small for
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gestational age births, pregnancy loss and stillbirths,
birth weight of live born babies, newborn length, the
need for neonatal resuscitation, neonatal admissions to
an intensive care unit, time from delivery to cord clamping, unanticipated or extended hospitalizations, breastfeeding practices and maternal well-being (quality of
life).
In consideration of current Anaemia Mukt Bharat
interventional guidelines for anaemia treatment in
pregnant women [11], two additional secondary
outcomes will be assessed: (1) participant need for
“rescue therapy” or measures implemented for
management of severe anaemia after a drop in Hb
concentration to <7 g/dL at any time after treatment is
initiated and (2) referral of a participant, regardless of
study arm, to a higher level of care (CHC, Taluka
hospital, or District Hospital/Tertiary Care Centre) for
further investigation of the cause of anaemia due to <1
g/dL improvement in Hb based upon analysis of blood
collected at 26–30 weeks of pregnancy.
Participant timeline {13}

The projected timeline for this study is approximately 42
months and will consist of a 7-month preparatory phase,
28 months for recruitment, treatment and follow-up, as
well as a final 5-month phase for data cleaning and analysis. This is summarized in Table 1.
Sample size {14}

The sample size for RAPIDIRON is primarily driven by
the comparison of LBW risk. The true risk of LBW is
assumed to be 25% in the oral iron arm based upon the
LBW estimate of 21% found in a similar population with
a Hb level at delivery of 7–9.9 g/dL but with fewer rural
sites [15]. Parks et al. estimate used data from
geographic clusters participating in the Eunice Kennedy
Shriver National Institute of Child Health and Human
Table 1 Study timeline

Page 7 of 16

Development (NICHD) Global Network’s Maternal
Newborn Health Registry for Jawaharlal Nehru Medical
College’s (JNMC) as well as data from the same registry
for clusters located near Nagpur, India, and in Pakistan.
Assuming a true LBW risk of 25% in the oral iron
group, a final sample of 1332 per group would give 80%
power to detect a 20% relative reduction (relative risk of
0.8; 20% LBW risk in each of the IV iron groups) at the
alpha=0.0245 level. One interim analysis when 1/3 of the
information on LBW is available is planned. With pvalue boundaries of 0.000026 at the interim analysis and
0.02449 at the final analysis, based on 10,000
simulations, with evaluable data on 1332 participants per
arm (444 per arm at the interim analysis), and assuming
both IV iron arms have true risk of LBW of 20%, the
study design provides a 1.6% probability of stopping
early for efficacy, approximately 80% probability of
concluding an a priori-selected IV arm has lower LBW
risk than the oral arm, and greater than 90% probability
of concluding at least one of the IV arms is better than
the oral iron arm. Approximately 4320 pregnant women
will need to be randomized 1:1:1 to each of the three
study arms assuming that 7.5% or less of participants
have missing birth weight data (due to stillbirth and
other reasons). Each of the two research sites (based in
either Karnataka or Rajasthan) will enrol and randomize
no more than 60% of all study participants.
With 1332 study participants per group, the study
provides greater than 95% power to detect differences in
risk of non-anaemia of at least 10% at the alpha=0.0005
level; as such the study is well powered for this outcome
assuming that the true risk approaches the anticipated
difference of 30% based on similar studies.
Recruitment {15}

Approximately 16,000 pregnant women will be screened
for low Hb at their first antenatal visit at participating

Derman et al. Trials

(2021) 22:649

CHCs and PHCs. This sample size should achieve an
adequate number of pregnant women who are
subsequently determined eligible to be randomized
equally to each of the three study arms. Recruitment and
randomization of participants will continue until study
data provide confidence that a minimum of 1332
randomized participants in each arm have evaluable
primary outcome data.
Assignment of interventions: allocation
Sequence generation {16a}

Randomization will be stratified by enrolment site, with
the two Indian research sites of Belagavi, Karnataka and
Jaipur, Rajasthan comprising the two randomization
strata. Randomization sequences will be generated for
each stratum using a computer-generated algorithm
based upon a randomly permuted block design with randomly varied block sizes as specified in a detailed
randomization plan to which all study investigators,
other than the coordinating centre randomization statistician, are masked.
Concealment mechanism {16b}

The block sizes will be known only to personnel
responsible
for
the
randomization
algorithm.
Randomization assignments will be placed in
sequentially numbered opaque envelopes by a
designated pharmacist, grouped by sets of 12, and stored
at the central research coordinating office of each
research site. Envelopes will be distributed monthly to
each CHC/PHC in sets of 12 (e.g. set 1 [envelopes 1–12]
to PHC 1, set 2 [envelopes 13–24] to PHC 2, sets 3 and
4 [envelopes 25–48] to PHC 3, etc.) based on projected
enrolment at the CHC/PHC for that month.
Implementation {16c}

Randomization assignments will be generated by the
statistical team at Thomas Jefferson University (TJU).
The sealed envelopes containing iron tablets/IV iron will
be available at the CHCs and PHCs. Accordingly, the
Medical Officer will randomize the participant. If the
participant is allocated to IV iron arm, then the Medical
Officer will calculate the dose and write it on the
randomization slip. The same randomization sequence
numbered envelops with iron tablets/IV iron (either
ferric derisomaltose/ferric carboxymaltose) will be
available at the CHCs. The pharmacist at the CHC will
match the randomization number on the envelope
issued at the CHC or PHC. Upon confirmation of the
number and opening of the envelope which designates
either ferric derisomaltose/ferric carboxymaltose, the
pharmacist will prepare the infusion (dose as per the
instructions written by a Medical Officer at the CHC or
PHC during randomization). The dose is double-
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checked based on the patient’s weight with subsequent
dispensing and provided to a staff nurse who will administer the IV iron to the participant under the supervision
of a CHC Medical Officer.
Assignment of interventions: blinding
Who will be blinded {17a}

The investigators at JNMC in Belagavi and SMSMC in
Jaipur will identify a specifically designated pharmacist
who will be assigned to the research team in their
respective site. They will assure compliance with the
specified randomization process and receipt of the
correct iron supplementation modality for each
participant. Oral iron use will not be masked. However,
blinding will occur for the two IV iron arms since IV
iron participants will know only that they have been
randomly assigned to receive an IV iron infusion
without knowing the specific arm (formulation) that will
be provided. Further, neither the point of care provider
nor the infusion team will know which IV iron
formulation was assigned. However, each pharmacist
responsible for preparing the IV Iron infusions for the
trial will not be blinded. When a participant arrives for
an infusion, the pharmacist will collect an infusion order
provided to the participant and prepare the appropriate
IV formulation for infusion based on the randomization
ID list. The IV medication will ONLY be known to the
pharmacist, with all other clinical staff blinded as to
which of the two IV formulations is being used.
Procedure for unblinding if needed {17b}

The participant consent form clearly indicates that if
there is a requirement to release study information
regarding participant treatment associated with receive
emergency care if needed, an authorized staff person has
permission to gain access to a protected participant
record. All episodes of unblinding will be shared with
members of the Data and Safety Monitoring Board
(DSMB).
Data collection and management
Plans for assessment and collection of outcomes {18a}

A baseline survey will be conducted in at the CHCs and
PHCs in both Belagavi and Jaipur. This survey consists
of 3 questionnaires, one to be distributed to each of the
following 3 groups: (1) pregnant women between 24 and
34 weeks of gestation (thus not eligible for inclusion in
this trial), to explore the current practices about
antenatal care, compliance with anti-helminthic, iron
and folic acid, delivery details and out of pocket expenditure; (2) healthcare providers to better understand supply of resources to CHCs/PHCs and the management of
anaemia at these centres; and (3) administrators to gain
an understanding of the supply chain of medicines
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provided to CHCs/PHCs especially those medications
utilized in the RAPIDIRON trial.
A summary of the study procedures including
outcomes to be collected at specific study related visit
can be found in Table 2.
All personnel will undergo training to familiarize
themselves with the trial protocol. There will also be
appropriate training in research ethics and employment
of Good Clinical Practice (GCP) guidelines.
Study staff involved in administering and monitoring
the IV iron infusions will receiving procedure-specific
training and access to the study Manual of Operations
(MOO) for reference as needed.
Trained ultra-sonographers will be selected to perform
ultrasound examinations. They will undergo studyspecific training before starting to scan participants for
eligibility based upon gestational age. Detailed information on ultrasound procedures and standardization will
be available to staff in the study MOO. The American
College of Obstetricians and Gynaecologists (ACOG)
provides guidance on due date estimation using ultrasonography when an accurate Last Menstrual Period
(LMP) is unavailable. This information can be utilized

Table 2 Timing of study procedures
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by study team as needed and is described in the study
MOO.
Equipment used in the study will be standardized
throughout the study sites including weighing machines,
ultrasound equipment and laboratory equipment/assays.
Plans to promote participant retention and complete
follow-up {18b}

The role of the ASHAs (as described in the section
“Strategies to improve adherence to interventions {11c}”)
is to act as facilitators to promote participant clinic
attendance and retention of study participants.
Regardless of whether participants discontinue
treatment or deviate from the intervention protocol, all
information from participants will be collected through
the end of the trial, unless the participant withdraws
such consent.
Data management {19}

JNMC is responsible for the development of the
independent Data Management System (DMS) and
utilization of the database system for the RAPIDIRON
Trial. Data will be collected primarily through the use of
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paper-based forms. JNMC has successfully used the Research Electronic Data Capture (REDCap) system for
numerous research projects. This system is a secure web
application for building and managing online surveys
and databases, and it offers a secure, privacy compliant
web-based electronic data capture and maintenance system. The data are stored in a centralized system. REDCap software requires each user to have their own
account, and user privileges are applied to ensure that
users have access only to data and information they need
and are authorized to have. REDCap can be accessed
from multiple sites from any computer or mobile device,
including PCs, Macs, tablets and mobile phones.
Data will be collected at the CHCs/PHCs and
transferred to regional data centres for data entry and
form storage and will be entered into computers using
the data management system developed by the research
team at JNMC. The data will then be transferred to TJU
utilizing REDCap. The DMS will involve a REDCap
server host and include project setup and form building
with validations and ranges.
Data quality validation with inbuilt quality checks will be
programmed into REDCap with external quality control.
Routine reports will be developed to include missing forms,
expected forms and participant follow-up schedules.
The data entry staff at each research site is responsible
for entering data from all completed paper forms into the
DMS. If data corrections are needed, study staff will enter
the corrections into the DMS, which will create an
automatic audit trail. The DMS retains built-in quality
checks to verify the accuracy and quality of the data
entered.
Confidentiality {27}

At the time of enrolment, each participant will be given
a unique screening ID number. All subsequent data
collection will be linked only to the ID number rather
than to a participant name.
In addition, the DMS is password-protected to ensure
that only trained, authorized personnel have access to
the data. The consent forms and locator forms linking
personal information to ID will be kept in securely
locked filing cabinets at each research site with only authorized staff having access. If unauthorized use of participant information is discovered, the onsite staff must
notify the senior research team and Principal Investigator (PI) along with plans to correct the problem and prevent further violations.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}

Blood samples will be collected at study-related visits as
detailed in Table 2. Samples will be collected at the
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locations detailed in Table 3. As two laboratories will be
utilized, one at each study site, each employing daily
controls, these processes will provide additional validation of results.
A mobile research team will be utilized in this trial to
ensure the necessary assessments and sample collections
are performed as planned. They will be responsible for
carrying out study related procedures including: assisting
Medical Officers in screening and enrolment, arranging
transport to a central facility for eligibility assessment,
obtaining study-specific blood draws at scheduled visits,
providing appropriate newborn weight and height assessment within 72 h of delivery and maintaining study
logs. They will be contacted by a participant’s CHC/
PHC/birthing facility/ASHA/relative or the participant
whenever a delivery is anticipated or their presence is
required.
Immediately after collection, the samples will be
stored upright at 2 to 8 °C. Samples should be
transported from the CHCs/PHCs to the central lab
within 6 h of collection. Those specimens ready for
transport will be stored in an insulated chiller box
containing ice packs and a thermometer to record the
transportation temperature. Once specimens arrive at
the laboratory, the laboratory staff who receives the
samples must complete the Laboratory Requisition Form
(LRF). The specimens will then be subjected to
processing at the respective site laboratories: KLE HiTech Clinical Lab, Belagavi and SMS MC Clinical Lab
Jaipur.
The following procedures will be carried out to ensure
quality control of sample analysis throughout the trial:
(1) the Lyphochek Anaemia Control (BIORAD).
Analytes: Ferritin, Folate, Iron (TIBC/UIBC), Vitamin
B12. Such controls will be run each time study samples
are to be analysed; (2) an internal QC process has been
established for study samples; (3) both laboratories will
participate in protocol-specific EQA testing; and (4) proficiency programme provider: BioRad for Biochemical
assays and All India Institute of Medical Sciences
(AIMS)/Christian Medical College (CMC) Vellore for
haematology parameters.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}

The primary analysis for anaemia will compare each IV
iron arm to the oral iron arm with respect to the
percentage of participants who achieve Hb of >11 g/dL
at either a 30–34-week antenatal visit or prior to
delivery using a Cochran-Mantel-Haenszel (CMH) chisquare test stratified by enrolment site at the 0.0005
level. The CMH-adjusted risk ratio and associated
99.95% confidence interval will be calculated for both
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Table 3 Blood sample collection sites
Visit number

Collection site

Visit #2: (12–16 weeks’ gestation)

Respective hospitals in Belagavi and Jaipur
Belagavi: KLES Dr. Prabhakar Kore Charitable Hospital and Medical Research Centre
Jaipur: SMS Medical College and Hospital

Visit #4: 2 weeks post-treatment

CHC/PHC

Visit #5: 20–24 weeks gestation

CHC/PHC

Visit #6: 26–30 weeks’ gestation

CHC/CHC

Visit #7: 30–34 weeks’ gestation

CHC/PHC

Visit #8: At delivery

Participant’s Delivery Location

Visit #9: 42 days post-delivery

CHC/PHC

comparisons. No interim efficacy analysis is planned for
the anaemia outcome.
Each IV arm will be compared to the oral iron arm
with respect to risk of LBW using a CMH chi-square
test stratified by enrolment site at the 0.000026 level
when data are available on at least 444 participants per
group (1/3 of expected information). The study can be
stopped for efficacy if either IV arm shows significantly
lower risk of LBW at the interim analysis. Assuming that
the study is not stopped early, the final tests will be performed at the 0.02449 level. Stopping boundaries were
calculated using a Lan-DeMets spending-function approach with O’Brien-Fleming bounds. The CMHadjusted risk ratio and associated 97.55% confidence
interval will similarly be calculated for both comparisons. If the study is prematurely stopped early based on
the results of LBW data, analysis of the anaemia endpoint will be performed at the 0.025 level.
The primary analysis will be performed using the
intent to treat (ITT) cohort. Missing anaemia and LBW
data will be imputed using multiple imputation. The
exact method of imputation will be specified in the
statistical analysis plan prior to analysis. Fifty data sets
will be imputed and the Wilson-Hilferty transformation
will be applied to the CMH statistics fit to each data set
[31, 32]. Results will be pooled using the method of
Rubin to calculate the overall test of significance [33].
The log (relative risk) estimates of each imputed data set
will similarly be combined.
Analysis of categorical secondary outcomes with
respect to treatment arm differences will use generalized
linear models to estimate relative risks and associated
confidence
intervals.
Analysis
of
continuous,
longitudinally measured, secondary outcomes with
respect to treatment arm differences will use mixed
effects linear regression, accounting for correlation
among repeated measurements over time and adjusting
for site as a random effect. Mean differences between
randomization groups will be estimated from the model
results at each measurement time along with
appropriate confidence intervals.

Association of Hb levels at delivery with LBW delivery
will be evaluated using logistic regression. For this
analysis, Hb levels will be categorized using the WHO
definitions for severity: < 7 g/dL (severe), 7–9.9 g/dL
(moderate), 10–10.9 g/dL (mild) and >11 g/dL (nonanaemic or normal). If one or both of the IV iron
formulations are demonstrated to be effective in
transitioning women to non-anaemic status (Hb >11g/
dL) in the third trimester of pregnancy at either or both
of two timepoints prior to delivery, or if one or both IV
iron formulations are effective in reducing the risk of
LBW deliveries, a series of secondary exploratory analyses will be performed to identify baseline factors that
are predictive of treatment success. The objective of
these analyses will be to support future implementation
of the treatment regimen in broad populations by identifying subpopulations most likely to benefit from the
treatment regimen. Separate logistic regression models
will be constructed for the anaemia and LBW outcomes,
with predictors to include Hb levels at the time of
randomization as well as TSAT and ferritin levels and
other baseline characteristics identified in the Statistical
Analysis Plan.

Interim analyses {21b}

An interim analysis for efficacy for the LBW outcome
will be performed when data are available on at least
444 participants per treatment arm (1/3 of expected
information). Using stopping boundaries from a LanDeMets spending function with O’Brien-Fleming
bounds, we set α1=0.000026 so that the study could
be stopped if the comparison of either IV arm to the
oral arm had p<0.000026. Assuming the observed risk
of LBW is 25% in the oral arm, this would occur if
the observed risk of LBW in a particular iron arm
were 13.7% or less. To maintain an overall type-I
error rate of 0.0245 for each IV vs. oral comparison,
if the null hypothesis is not rejected at the interim
analysis, the final comparisons for LBW will be completed at the 0.02449 level.
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Assuming the study is not stopped for efficacy, one
formal interim analysis for futility will be completed
based on a data snapshot taken when the anaemia
outcome is available for 666 participants per group (1/2
of expected information). The interim analysis for
futility will involve the conditional power associated
with two hypothesis tests: the two-degree of freedom
CMH test of differences in prevalence of anaemia prior
to delivery across the three treatment arms and the twodegree of freedom test of differences in risk of LBW
across the three treatment arms. If analyses for both primary efficacy outcomes show a conditional power of less
than 0.2 based on the observed data at the time of the
interim analysis and the assumed effect for the study design, the DSMB may consider recommending that the
study be stopped.
The analysis for safety will have two components.
First, point and 97.5% confidence interval estimates of
the risk of mortality and incidence of at least one SAE
will be developed for each of the three treatment arms.
If the interval estimates provide evidence that either of
the active IV iron treatment arms has significantly
higher risk of either mortality or adjudicated SAE
incidence than the active comparator arm (oral iron),
the DSMB will consider recommending stopping
enrolment for that active IV iron treatment arm. In
making the recommendation, the DSMB can consider
the overall risk profile of the treatment arms and any
evidence of efficacy that has been accumulated at the
time of the interim analysis.
Methods for additional analyses (e.g. subgroup analyses)
{20b}

IV iron arms will be descriptively compared with respect
to the proportion of LBW births and proportion of nonanaemic patients by estimating the CMH-adjusted risk
ratio and associated 95% confidence interval. An additional analysis comparing each IV iron arm to oral iron
will be performed on the per protocol cohort.
An exploratory Hb-based subgroup analysis will be
performed to estimate the effect of treatment on conversion to non-anaemia status and the risk of LBW solely
by level of Hb measured prior to randomization (between the beginning of week 14 and 17 weeks 0 days of
pregnancy). Hb-based subgroups will be defined based
on clinical considerations but may be collapsed depending on the sample sizes within each group.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}

The ITT cohort includes all randomized study
participants using treatment group assignments as
randomized. Missing anaemia and LBW data will be
imputed using multiple imputation as described above.
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The exact method of imputation will be specified in the
statistical analysis plan prior to analysis. Secondary
outcomes will not be imputed.
The per-protocol cohort includes all study participants
randomized to IV who receive the complete, recommended dosage of the randomly assigned IV iron formulation between the beginning of the 14th week of
pregnancy and prior to the beginning of the 17th week
and all study participants assigned to oral iron therapy
who take equal to or greater than 80% of prescribed
pills. Use of any non-study-provided iron preparation
post-randomization will represent an exclusion for the
purpose of the per protocol analysis. Additionally, a participant assigned to an IV iron arm that receives only a
portion of the recommended single infusion dosage for
the randomly-assigned IV iron formulation will be
excluded.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}

Data sharing will be granted in accordance with the
details registered with the Clinical Trial Registry of India
(CTRI). Individual participant data that underlie the
results reported in specific publications arising out of
the trial, after de-identification (text, tables, figures and
appendices) will be shared. Additionally, the study
protocol, statistical analysis plan and informed consent
forms will be shared.
These files will be viewable by researchers whose
proposed use of the data has been approved by the Trial
Steering Committee. The data will be available for
analyses necessary to achieve aims in the approved
proposal. Data will be available via communication with
representatives of the Trial Steering Committee by
email: Dr Richard Derman (Richard.Derman@jefferson.
edu) and Dr M B Bellad (mbbellad@hotmail.com). Data
will be available beginning 3 months and ending 5 years
following article publication.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}

The Trial Steering Committee consists of the study PI,
Dr. Richard Derman; co-investigators from the Belagavi
site, Dr. Shivaprasad Goudar and Dr. Mrutyunjaya Bellad; and co-investigators from the Rajasthan site, Dr.
Sudhir Mehta and Dr. Kusum Gaur. Each of the 3 collaborative research groups involved in this trial at Belagavi, Jaipur and TJU will have established a senior
leadership team with team members meeting on a
weekly basis. This specified Steering Committee will be
responsible for overall oversight and governance of the
trial with the final responsibility remaining with the PI.
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The trial coordinating centre will reside at JNMC and
having responsibility for coordinating daily operations
for both the Belagavi and Jaipur sites. This includes
ongoing training and management of study site staff.
The study Technical Advisory Group (TAG) will
convene on a biannual basis to provide technical
assistance and oversight.
Composition of the data monitoring committee, its role and
reporting structure {21a}

An independent DSMB will be comprised of five
individuals: a chair and four supporting members. All
members of the DSMB will be free of conflicts of
interest to enable performance of their duties in an
unbiased manner.
The duties to be performed by the DSMB include
reviewing serious adverse events (SAEs), and adverse
events (AEs) and unanticipated problems posing risks to
study participants or their foetuses/offspring; assuring that
the research is conducted in a manner to minimize risk
and promote safety; assessing data quality, participant
recruitment, accrual and retention; and preparing reports
that outline DSMB recommendations and providing them
to the research team. The DSMB will meet approximately
every 6 months until all study participants have been
followed and data collected on outcomes through 42 days
post-delivery. Further information on the DSMB can be
found in the study protocol and MOO.
A designated Chief Quality and Safety Officer will also
serve as the senior biostatistical consultant for the
RAPIDIRON Trial. This individual will work with the
Data Management System (DMS) at JNMC and the
senior statistician at TJU to monitor the ongoing quality
of study operations and safety of study participants. He
will also serve as the primary interface between the
study investigators and the DSMB.
Given the importance of distinguishing serious adverse
drug reactions specifically related to intravenous iron
infusions from non-serious reactions that commonly
occur with the use of any intravenous medication, two
experts familiar with the use of IV iron have been designated as adjudicators.
The study teams from both Belagavi and Jaipur will
report possible SAEs in a timely manner to the
adjudicators. Two adjudicators will conduct rapid
reviews and provide case by case validation of all SAEs
and comment on the clinical management of each of
these cases. These reports will be submitted to the study
PI and site PIs, who will share the information with the
DSMB in a timely manner.
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occurs during the course of the trial and requires
treatment should be reported and the AE CRF
completed.
The RAPIDIRON trial is recruiting pregnant women
as participants. It is expected that these women will
experience a range of obstetric-related symptoms during
pregnancy, labour and the postpartum period. These
should not be recorded as AEs unless the event is of unusual severity, intensity, duration or frequency.
When uncertainty exists as to whether a condition is
to be reported as an AE or SAE such cases should be
reported to and monitored by the adjudicators.
A serious adverse event (SAE) involves a randomized
participant that initiated treatment OR the foetus or
newborn of such a participant. To qualify as an SAE, at
least one of the following criteria must apply to the
event: (1) results in a maternal or neonatal death, or a
foetal death greater than 20 weeks’ gestation; (2) is lifethreatening; (3) requires an unanticipated hospitalization
or prolongs an existing hospitalization; (4) results in persistent or significant disability or incapacity; or (5) represents other serious or unexpected adverse events that a
study investigator feels should be reported, including
need for resuscitation.
Study drug reactions will be reported as an SAE if they
meet an SAE criterion (above) and will be documented
as an SAE that is related to the use of the study drug
only when confirmed by adjudication.
SAEs will be reported to, and monitored by, the
DSMB.
At each scheduled DSMB meeting after study
recruitment, SAE/AE data and a report summarizing
recruitment and participant status will be prepared for
review and discussion. Following its deliberations, the
DSMB will issue any recommendations it may have and
specify that the study should continue based upon
absence of significance safety concerns.
Frequency and plans for auditing trial conduct {23}

The study PI and statisticians will meet monthly to
review the data and evaluate its quality and safety. They
will provide a monitoring report with deidentified data
for the study funder on a quarterly basis. The data will
also be reviewed by an independent DSMB who will
meet every 6 months throughout the trial.
The study funder (CIFF) will employ an independent
clinical research organization (CRO) to routinely audit the
study and monitor the quality and safety of study practices.

Adverse event reporting and harms {22}

Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}

An adverse event (AE) is defined as any untoward
medical occurrence in a study participant. Any AE that

The senior research team will meet weekly to review all
concerning issues. Any protocol amendments will be
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reviewed by all relevant parties including all site IRBs as
necessary. Changes to the protocol that would alter the
consent process will be communicated to study
participants in an appropriate manor. The means for
communicating any necessary changes to study
participants will be determined by the research team
taking into consideration the level of safety concern
involved and with advice from the DSMB.
Dissemination plans {31a}

Results of the study will be disseminated through
meetings and publications. In disseminating results to
study participants the research team will be consistent
with the guidelines of the CTRI.

Discussion
This study will assess the effectiveness of two
formulations of single-dose IV iron in the treatment of
IDA in pregnant women and reducing low birth weight
deliveries when compared with oral iron, the current
standard of care.
Though current research has demonstrated IV iron to
be a safe and effective treatment of IDA in pregnant
women, there remains a scarcity of large, quality trials
that assess the effect on maternal and neonatal
outcomes of iron administration in anaemic, pregnant
women. The Cochrane Review indicates the need for
assessing efficiency of iron treatment in pregnancy,
specifically newer approaches such as single-dose IV
iron. This study is unique in that it will address generalisability of this intervention through a more rigorous assessment on a large scale in a lower-middle income
country. It also has the potential to influence the refinement of India’s health organizations current guidance on
IDA treatment and lead to better long-term outcomes.
Another important aspect of this study is the
independent economic analysis to be performed by
experts in the field of health economics and costeffectiveness of healthcare interventions. The study will
report the cost-effectiveness when employing each
single-dose IV iron formulation compared to oral therapy in the treatment of IDA in pregnant women. One
aim is to demonstrate the economic feasibility of scaleup of this treatment approach and its subsequent usefulness as a treatment for IDA in pregnant women in other
low- and middle-income countries with constrained resources. There is also an opportunity to analyse the economic impact of reducing low-birthweight and iron
deficiency in the offspring on the cost of interventional
programmes needed to modify the neurobehavioral effects of these two outcomes.
A potential challenge to consider is the impact that
COVID-19 cases in India might have on recruitment
and increased costs for personal protective equipment
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(PPE); however, every effort is being made to minimize
the effects of these challenges.
While we have complete data for India’s National
Family Health Survey (NFHS-4) for 2015–2016, new
data for India’s NFHS-5 is currently being collected. The
new data for Rajasthan is not yet available, however, the
figures for Karnataka show an increase in the number of
both children and pregnant women who are anaemic
when compared to the 2015–2016 data [34]. This further
underscores the need for a new, easily accessible and
cost-effective approach for treating anaemia and timely
importance of this study.

Trial status
Protocol Version 1.2, March 8, 2021. Recruitment began
on March 15, 2021. The projected completion date for
recruitment is February 28, 2023.
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